Crossmark Global Holdings Inc. Sells 66 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
Crossmark Global Holdings Inc. lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 1.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission.
What Makes Charles River Labs (CRL) an Investment Bet?
Upslope Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. Q4 was the most challenging quarter for upslope.
RiverWater Partners Sustainable Value Strategy Trimmed its Investment in Charles River Laboratories (CRL)
Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A copy of the letter can be downloaded here. The strategy outperformed its benchmark,
Charles River Laboratories International (NYSE:CRL) Downgraded by William Blair to Market Perform
Charles River Laboratories International (NYSE:CRL – Get Free Report) was downgraded by equities research analysts at William Blair from an “outperform” rating to a “market perform” rating in a report released on Wednesday,
Charles River downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Charles River (CRL) to Market Perform from Outperform.Invest with Confidence: Follow TipRanks' Top Wall Street
Charles River Labs downgraded at William Blair on less early-stage R&D spending
William Blair downgraded Charles River Laboratories to market perform from outperform citing a likely decline in early-stage R&D spending from large pharmaceutical companies. Analysts Max Smock and Christine Rains said that they are concerned about the near-term outlook for the contract research organization "given our view that in light of the
Barchart on MSN1d
Charles River Laboratories' Quarterly Earnings Preview: What You Need to Know
Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical ...
Seeking Alpha2d
CRL Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and ...
FiercePharma4d
Atara's Ebvallo and pipeline candidate put on clinical hold in US after partner's failed plant inspection
After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...
What Analysts Are Saying About Charles River Stock
Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...
Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued
Abeona Therapeutics Inc.'s promising gene therapy for RDEB, potential FDA approval, undervalued stock, and key risks. Click ...
Atara Biotherapeutics Faces Strategic Uncertainty Amid FDA Hold and CRL Issues
H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating yesterday.Invest with Confidence: ...
The Pharma Letter3d
Clinical hold follows CRL for Atara
T-cell immunotherapy company Atara Biotherapeutics closed 8% lower on Tuesday, having lost 41% of its stock market value on ...
Hosted on MSN3d
Atara’s T cell programmes hit with clinical hold after third-party site woes
The FDA placed a clinical hold on two Atara assets, following an inspection at a third-party site that also led to a CRL for ...